ResearchPhase I first-in-human dose-expansion study of the oral SF3B1 modulator H3B-8800 in lower-risk myelodysplastic syndrome
ResearchOlutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
ResearchIntercurrent presentation of hairy cell leukemia and diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: a case report
ResearchPhase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B-8800 in lower-risk myelodysplastic syndrome
ResearchHypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia
ResearchCo-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML
ResearchBalancing Activation and Repression: CoREST-p300 Antagonism Controls Retinoic Acid-Driven Differentiation in AML
ResearchOlutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome
ResearchOlutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort
ResearchVenetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia
ResearchOlutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)
ResearchFinal phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
ResearchPhase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms